December 23, 2009.
Sanofi-Aventis is to buy US consumer health company Chattem in a $1.9 bn (Euro 2.71 bn) cash deal, according to a report in the UK Financial Times. Chattem sells products such as Icy Hot cream and Selsun Blue anti-dandruff shampoo; the acquisition will provide the French company with “the ideal platform in the US consumer healthcare market,” according Sanofi boss Chris Viehbacher.
Sanofi will pay $93.50 (Euro 133.71) a share for Chattem; the offer was at a 34 per cent premium to Chattem’s closing stock price on Friday 18th December. The US company’s shares leapt 32.8 per cent to $92.94 in midday trading.
The deal is expected to close in the first quarter of 2010. Sanofi will retain Chattem’s two manufacturing plants in Tennessee, US, and also build a third.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.